Unexpected doxorubicin-mediated cardiotoxicity in sisters: Possible role of polymorphisms in histamine n-methyl transferase

Abstract

The anthracycline anticancer agent doxorubicin has long been recognized to induce a dose-limiting cardiotoxicity and may be associated with genes relevant to doxorubicin disposition. Recent reports suggest a role for a number of single nucleotide polymorphisms in anthracycline cardiotoxicity in children. We describe two adult sisters with anthracycline cardiotoxicity that developed after a relatively low dose of doxorubicin. One sister carried the variant genotype for histamine N-ethyl transferase (HNMT, rs17583889) while the other was heterozygous, suggesting a similar role for these genotypes in adults with anthracycline cardiotoxicity. Although this requires further study, these genotypes may be important in the clinical dosing, or use of the liposomal formulation of doxorubicin.

Keywords

Doxorubicin cardiotoxicity polymorphism

Get full access to this article

View all access options for this article.

References

Gianni

Herman

Lipshultz

. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777–3784.

Berthiaume

Wallace

. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 2007; 23: 15–25.

Wojnowski

Kulle

Schirmer

. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicininduced cardiotoxicity. Circulation 2005; 112: 3754–3762.

Couture

Nash

Turgeon

. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev 2006; 58: 244–258.

Dell’Acqua

Polishchuck

Fallon

. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther 1999; 10: 1269–1279.

Deng

Wojnowski

. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007; 7: 129–134.

Gille

Nohl

. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol 1997; 23: 775–782.

Ambrosone

Ahn

Singh

. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005; 65: 1105–1111.

Forrest

Gonzalez

Tseng

. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000; 60: 5158–5164.

10.

Slupe

Williams

Larson

. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc Toxicol 2005; 5: 365–376.

11.

Olson

Bedja

Alvey

. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003; 63: 6602–6606.

12.

Gayle

Sachidanandam

Kolesar

. Unexpected doxorubicin-induced cardiomyopathy in sisters. Int Canc Conf J 2012; 1: 15–18.

13.

Visscher

Ross

CJD

Rassekh

. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422–1428.

14.

Blanco

Sun

Landier

. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J Clin Oncol 2012; 30: 1415–1421.

15.

Zhang

Berger

. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemother Pharmacol 2003; 51: 407–414.